Sutro Biopharma (STRO) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$45.7M

Revenue (quarter)

$9.8M

Revenue growth (year over year)

−84.57%

Gross profit (trailing twelve months)

$45.7M

Gross margin

100.00%

Net income (trailing twelve months)

−$180.6M

Net income (quarter)

−$38.5M

Net income growth (year over year)

−235.10%

Net margin

−395.25%

Return on equity

—

EPS (trailing twelve months)

−$17.37

Book value per share

−$6.23

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

153.13%

Payout ratio

—

Dividend yield

—

Company profile

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

• Is Sutro Biopharma (STRO) profitable?

  No. Sutro Biopharma reported a net loss of $180.6M over the trailing twelve months.

• How much revenue does Sutro Biopharma (STRO) make?

  Sutro Biopharma generated $45.7M in revenue over the trailing twelve months, down 84.57% year over year.

• How do I buy stock in Sutro Biopharma (STRO)?

  STRO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.